- In May 2022, Bruker launched novel 7-Tesla and 9.4-Tesla preclinical MRI magnets, designed to enhance the precision of imaging in clinical research. These advanced MRI systems offer higher resolution imaging, enabling researchers to gain more detailed insights into disease mechanisms at the molecular level. The new technology is expected to improve the efficiency and accuracy of preclinical trials, particularly in oncology, neurology, and cardiovascular research. This development will impact the market by advancing imaging capabilities, accelerating drug development, and enabling more precise assessments of therapeutic efficacy
- In March 2022, Fujifilm India introduced a new range of products at the 74th IRIA (Indian Radiological and Imaging Association) Conference. The company unveiled advanced imaging solutions, including diagnostic imaging technologies designed to enhance healthcare delivery in India. These products aim to improve the quality of medical imaging and assist healthcare professionals in providing more accurate diagnoses. The introduction of these technologies will have a significant impact on the market by expanding access to high-quality imaging solutions, ultimately enhancing the capabilities of medical institutions and accelerating advancements in clinical trials
- In January 2022, ERT and BioClinica merged to form Clario, a leading technology solutions company for clinical trial innovation. This merger combines ERT's clinical trial data collection expertise and BioClinica’s imaging solutions, creating a unified platform to enhance trial efficiency. Clario aims to streamline clinical trial processes, offering integrated services in data collection and imaging, improving accuracy, speed, and patient outcomes. This development is expected to have a significant impact on the market by advancing clinical trial technology and driving innovation
- In November 2021, Clario and XingImaging expanded their partnership to deliver PET imaging solutions for clinical trials in China. This development aims to enhance the accuracy and efficiency of clinical trials by integrating advanced PET imaging technology with Clario's data collection and analytics capabilities. The partnership will enable pharmaceutical companies and CROs to conduct more precise trials, improving the monitoring of disease progression and treatment efficacy. This expansion will significantly benefit the market by providing access to high-quality imaging services in China, helping accelerate drug development in the region
